Clinical applications for host modulatory therapy.
A better understanding of the pathogenesis of periodontitis has resulted in pharmacotherapeutic advancements that address both the microbes and the host response, leading to improved management of this chronic progressive disease by the dental practitioner. The adjunctive use of host modulatory therapy can enhance therapeutic responses, slow the progression of the disease, and allow for more predictable management of patients, particularly in those patients at increased risk caused by factors beyond the reach of conventional therapeutic approaches. This article reviews the pathogenesis and risk factors associated with periodontitis and addresses, in detail, the concept and clinical use of host modulation as a therapeutic strategy.
Ryan
Maria Emanuel
ME
State University of New York at Stony Brook, School of Dental Medicine, Stony Brook, New York, USA.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002908:Chronic Disease; D018450:Disease Progression; D004198:Disease Susceptibility; D004318:Doxycycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D061965:Matrix Metalloproteinase Inhibitors; D010518:Periodontitis / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D012307:Risk Factors; D019714:Tissue Inhibitor of Metalloproteinases / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007155:Immunologic Factors; D061965:Matrix Metalloproteinase Inhibitors; D019714:Tissue Inhibitor of Metalloproteinases; D004318:Doxycycline